Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

141. An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study (PubMed)

An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study Nongenetic health providers may lack the relevant knowledge, experience, and communication skills to adequately detect familial colorectal cancer (CRC), despite a positive attitude toward the assessment of history of cancer in a family. Specific training may enable them to more optimally refer patients to genetic counseling.The aim of this study was to develop an e (...) module to help surgeons-in-training and gastroenterologists in recognizing a hereditary predisposition in patients with CRC. The e-learning led to improvements in attitude toward the assessment of cancer family history, knowledge on criteria for referral to genetic counseling for CRC, and comprehension of communication skills.©Kirsten Freya Lea Douma, Cora M Aalfs, Evelien Dekker, Pieter J Tanis, Ellen M Smets. Originally published in JMIR Medical Education (http://mededu.jmir.org), 18.12.2017.

Full Text available with Trip Pro

2017 JMIR medical education

142. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment

2017 CADTH - Pan Canadian Oncology Drug Review

143. Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection

Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection Intraoperative ultrasonography during open surgery for colorectal cancer may be useful for the detection of unrecognized liver metastases. Laparoscopic ultrasonography (LUS) for the detection of unrecognized liver metastasis has not been studied in a randomized trial. This RCT tested the hypothesis that LUS would change the TNM stage and treatment strategy.Patients with colorectal cancer (...) of colorectal cancer is not recommended. Registration number: NCT02079389 (http://www.clinicaltrials.gov).© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

2017 EvidenceUpdates

144. Is whole-colon investigation by colonoscopy, computerised tomography colonography or barium enema necessary for all patients with colorectal cancer symptoms, and for which patients would flexible sigmoidoscopy suffice? A retrospective cohort study

Is whole-colon investigation by colonoscopy, computerised tomography colonography or barium enema necessary for all patients with colorectal cancer symptoms, and for which patients would flexible sigmoidoscopy suffice? A retrospective cohort study Is whole-colon investigation by colonoscopy, computerised tomography colonography or barium enema necessary for all patients with colorectal cancer symptoms, and for which patients would flexible sigmoidoscopy suffice? A retrospective cohort study (...) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} In patients referred to hospital with suspected colorectal cancer, symptom profiles are associated with cancer site

2017 NIHR HTA programme

145. Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future (PubMed)

Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future 29662926 2018 11 14 2341-4545 25 2 2018 Mar GE Portuguese journal of gastroenterology GE Port J Gastroenterol Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future. 55-56 10.1159/000481861 Oliveira Ferreira Alexandre A Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal. eng Editorial 2017 11 30 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Adenoma Colorectal cancer (...) Screening 2017 09 21 2017 09 27 2018 4 18 6 0 2018 4 18 6 0 2018 4 18 6 1 ppublish 29662926 10.1159/000481861 pjg-0025-0055 PMC5892355 Int J Cancer. 2015 Mar 1;136(5):E359-86 25220842 Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216 17253456 Gastroenterology. 2017 Jul;153(1):307-323 28600072 N Engl J Med. 2013 Sep 19;369(12):1095-105 24047059 JAMA. 2000 Oct 18;284(15):1954-61 11035892 N Engl J Med. 2014 Apr 3;370(14):1298-306 24693890

Full Text available with Trip Pro

2017 GE Portuguese journal of gastroenterology

146. QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer (PubMed)

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer A Quality-adjusted Time WIthout Symptoms of disease or Toxicity (QTWiST) analysis was carried out to assess quality-adjusted survival time in the RECOURSE trial of trifluridine/tipiracil versus placebo in pretreated metastatic colorectal cancer (mCRC).Duration of overall survival in the RECOURSE trial (n=798 patients) was partitioned into three discrete health states: toxicity (TOX), time without

Full Text available with Trip Pro

2017 ESMO open

147. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial (PubMed)

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal analysis of quality of life (QoL) in RECOURSE. The aim of the present analysis was to assess proxies of QoL during

Full Text available with Trip Pro

2017 ESMO open

148. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. (PubMed)

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. The fecal immunochemical test (FIT) for detecting hemoglobin is used widely for noninvasive colorectal cancer (CRC) screening, but its sensitivity leaves room for improvement.To identify novel protein biomarkers in stool that outperform or complement hemoglobin in detecting CRC and advanced adenomas.Case-control study.Colonoscopy-controlled referral population from several centers.315 stool (...) samples from one series of 12 patients with CRC and 10 persons without colorectal neoplasia (control samples) and a second series of 81 patients with CRC, 40 with advanced adenomas, and 43 with nonadvanced adenomas, as well as 129 persons without colorectal neoplasia (control samples); 72 FIT samples from a third independent series of 14 patients with CRC, 16 with advanced adenomas, and 18 with nonadvanced adenomas, as well as 24 persons without colorectal neoplasia (control samples).Stool samples

2017 Annals of Internal Medicine

149. Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size (PubMed)

Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size Several studies reported that early tumour shrinkage (ETS) was associated with overall survival in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. However, appropriate time point and cut-off value for ETS remain unclear

Full Text available with Trip Pro

2017 ESMO open

150. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE (...) , SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival.FOXFIRE, SIRFLOX, and FOXFIRE-Global were randomised, phase 3 trials done in hospitals and specialist liver centres in 14 countries worldwide (Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal

Full Text available with Trip Pro

2017 EvidenceUpdates

151. Human microbiome signatures of differential colorectal cancer drug metabolism (PubMed)

Human microbiome signatures of differential colorectal cancer drug metabolism It is well appreciated that microbial metabolism of drugs can influence treatment efficacy. Microbial β-glucuronidases in the gut can reactivate the excreted, inactive metabolite of irinotecan, a first-line chemotherapeutic for metastatic colorectal cancer. Reactivation causes adverse drug responses, including severe diarrhea. However, a direct connection between irinotecan metabolism and the composition (...) in targeted subsets of patients. In total, this study reveals metagenomic mining of the microbiome, combined with metabolomics, as a non-invasive approach to develop biomarkers for colorectal cancer treatment outcomes.

Full Text available with Trip Pro

2017 NPJ biofilms and microbiomes

152. Colorectal Cancer Screening: What Is the Population's Opinion (PubMed)

Colorectal Cancer Screening: What Is the Population's Opinion Colorectal cancer (CRC) is the first cause of death by cancer in Portugal and mortality has been increasing in the last 30 years.During a raising awareness campaign performed by our Gastroenterology Department, in Setúbal, Portugal, an anonymous written questionnaire was developed and presented in order to evaluate the population's knowledge and attitude regarding CRC screening.The following results were reported: 140 persons; mean (...) age 54.6 years; 61.4% women; 22.1% had a family history of colorectal cancer. The main risk factors mentioned by the respondents were family history of CRC, previous history of intestinal polyps, and intestinal infection. Screening was considered useful by all respondents. About 60% of the respondents had been counselled, at least, on one screening technique, mainly by their general practitioner: colonoscopy in 31, fecal occult blood test in 44, and flexible sigmoidoscopy in 9. Most

Full Text available with Trip Pro

2017 GE Portuguese journal of gastroenterology

153. The association between metformin use and colorectal cancer survival among patients with diabetes mellitus: An updated meta-analysis. (PubMed)

The association between metformin use and colorectal cancer survival among patients with diabetes mellitus: An updated meta-analysis. Recent studies have reported conflicting results on the correlation between metformin use and outcomes in patients with colorectal cancer (CRC). A meta-analysis was performed to evaluate the efficacy of metformin therapy on the prognosis of CRC patients with type 2 diabetes mellitus (T2DM).We conducted a systematic search of PubMed, EMBASE, the Cochrane Library

Full Text available with Trip Pro

2017 Chronic diseases and translational medicine

154. P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring (PubMed)

P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring Placental-Cadherin (CDH3) is a cell adhesion molecule vital to cellular localization and tissue integrity. It is highly expressed in the placenta (PLC)and is overexpressed by many types of cancer. P-cadherin levels in colorectal cancer (CRC) remains poorly characterized. This study's purpose was to determine P-cadherin expression in CRC and normal tissues and to assess (...) plasma CDH3 levels in order to determine the relationship, if any, between cancer stage, P-cadherin expression and plasma CDH3 levels.An IRB approved plasma, tumor, and prospective data bank was utilized. CRC patients for whom tumor and normal colon tissue samples were available were enrolled. Tumor samples were OCT embedded and stored at -80C°. Total purified RNA was isolated from tissue samples and cDNA synthesized. CDH3 expression was analyzed by quantitative PCR (QPCR) using the SYBR Green

Full Text available with Trip Pro

2017 Oncoscience

155. CK20 mRNA Expression in Serum as a Biomarker for Colorectal Cancer Diagnosis: A Meta-analysis. (PubMed)

CK20 mRNA Expression in Serum as a Biomarker for Colorectal Cancer Diagnosis: A Meta-analysis. The aim of this study was to evaluate the diagnostic value of serumCK20 mRNA as a biomarker for colorectal cancer diagnosis by meta-analysis. Clinical studies related to serum CK20 mRNA expression for colorectal cancer diagnosis were searched in the databases of Pubmed, Cochrane Library, Embase, ISI Web of Knowledge, CNKI and Wanfang. The number of true positive (tp), false positive (fp), false (...) included in this meta-analysis. The diagnostic sensitivity and specificity were pooled by random effect model(I2>50%). The pooled diagnostic sensitivity and specificity of CK20 mRNA in serum as biomarker for colorectal cancer were 0.49 (95% CI:0.46 to 0.51) and 0.94 (95%CI:0.92-0.96) respectively. The pooled +LR and -LR were 10.90 (95%CI:5.78 to 20.55) and 0.51 (95%CI:0.45 to 0.57) respectively by random-effect method. The pooled DOR was 22.31 with the 95% CI of 11.65 to 42.71. The pooled area under

Full Text available with Trip Pro

2017 Open medicine (Warsaw, Poland)

156. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. (PubMed)

Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Population-based screening to prevent colorectal cancer (CRC) death is effective, but the effectiveness of postpolypectomy surveillance is unclear.To evaluate the additional benefit in terms of cost-effectiveness of colonoscopy surveillance in a screening setting.Microsimulation using the ASCCA (Adenoma and Serrated pathway to Colorectal (...) CAncer) model.Dutch CRC screening program and published literature.Asymptomatic persons aged 55 to 75 years without a prior CRC diagnosis.Lifetime.Health care payer.Fecal immunochemical test (FIT) screening with colonoscopy surveillance performed according to the Dutch guideline was simulated. The comparator was no screening or surveillance. FIT screening without colonoscopy surveillance and the effect of extending surveillance intervals were also evaluated.CRC burden, colonoscopy demand, life-years

2017 Annals of Internal Medicine

157. Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial

Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial Despite free colorectal cancer screening in France, participation remains low and low socioeconomic status is associated with a low participation. Our aim was to assess the effect of a screening navigation program on participation and the reduction in social inequalities in a national-level organized mass screening program for colorectal cancer by fecal-occult

2017 EvidenceUpdates

158. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation

Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling I M & Hyde C. Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling I M & Hyde C.. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technology Assessment 2017; 21(51) Authors' objectives Inherited mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes lead to an increased risk

2017 Health Technology Assessment (HTA) Database.

159. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economi

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economi The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review (...) and economic evaluation The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M & Hoyle M. Record Status This is a bibliographic record of a published health technology assessment from a member

2017 Health Technology Assessment (HTA) Database.

160. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation

Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Microsatellite instability and immunohistochemistry will identify most cases of Lynch syndrome in colorectal cancer but there is no high-quality evidence that screening improves long-term outcomes {{author}} {{($index , , , , , & . Tristan Snowsill 1, * , Helen Coelho 1 , Nicola Huxley 1 , Tracey Jones-Hughes 1 , Simon Briscoe 1 , Ian M Frayling 2 , Chris Hyde 1 1 Peninsula

2017 NIHR HTA programme